Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder

被引:213
|
作者
Krakowski, Menahem I.
Czobor, Pal
Citrome, Leslie
Bark, Nigel
Cooper, Thomas B.
机构
[1] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA
[2] NYU, Sch Med, New York, NY USA
[3] Albert Einstein Coll Med, Bronx, NY 10467 USA
[4] Dov Pharmaceut, Hackensack, NJ USA
[5] Columbia Univ, Coll Phys & Surg, New York, NY USA
关键词
D O I
10.1001/archpsyc.63.6.622
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Context: Violent behavior of patients with schizophrenia prolongs hospital stay and interferes with their integration into the community. Finding appropriate treatment of violent behaviors is of primary importance. Objective: To compare the efficacy of 2 atypical antipsychotic agents, clozapine and olanzapine, with one another and with haloperidol in the treatment of physical assaults and other aggressive behaviors in physically assaultive patients with schizophrenia and schizoaffective disorder. Design and Setting: Randomized, double-blind, parallel-group, 12-week trial. Physically assaultive subjects with schizophrenia or schizoaffective disorder who were inpatients in state psychiatric facilities were randomly assigned to treatment with clozapine (n=37), olanzapine (n=37), or haloperidol (n=36). Main Outcome Measures: Number and severity of physical assaults as measured by the Modified Overt Aggression Scale (MOAS) physical aggression score and the number and severity of all aggressive events as measured by the MOAS overall score. Psychiatric symptoms were assessed through the Positive and Negative Syndrome Scale (PANSS). Results: Clozapine was superior to both olanzapine and haloperidol in reducing the number and severity of physical assaults as assessed by the MOAS physical aggression score and in reducing overall aggression as measured by the MOAS total score. Olanzapine was superior to haloperidol in reducing the number and severity of aggressive incidents on these 2 MOAS measures. There were no significant differences among the 3 medication groups in improvement of psychiatric symptoms as measured by the PANSS total score and the 3 PANSS subscales. Conclusions: Clozapine shows greater efficacy than olanzapine and olanzapine greater efficacy than haloperidol in reducing aggressive behavior. This antiaggressive effect appears to be separate from the antipsychotic and sedative action of these medications.
引用
收藏
页码:622 / 629
页数:8
相关论文
共 50 条
  • [1] The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
    Madhusoodanan, Subramoniam
    Sinha, Abhishek
    Sajatovic, Martha
    Gupta, Sanjay
    Brenner, Ronald
    [J]. CURRENT DRUG SAFETY, 2006, 1 (03) : 227 - 241
  • [2] Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder
    Lerner, V
    Libov, I
    Kotler, M
    Strous, RD
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (01): : 89 - 98
  • [3] Antipsychotic Prescription Filling in Patients With Schizophrenia or Schizoaffective Disorder
    Reutfors, Johan
    Brandt, Lena
    Stephansson, Olof
    Kieler, Helle
    Andersen, Morten
    Boden, Robert
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 33 (06) : 759 - 765
  • [4] Antipsychotic Medication Adherence in Patients with Schizophrenia or Schizoaffective Disorder
    Reutfors, Johan
    Brandt, Lena
    Stephansson, Olof
    Kieler, Helle
    Andersen, Morten
    Boden, Robert
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 437 - 438
  • [5] CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder
    Sharma, RP
    Janicak, PG
    Bissette, G
    Nemeroff, CB
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1997, 154 (07): : 1019 - 1021
  • [6] Psychopathy and violent behavior among patients with schizophrenia or schizoaffective disorder
    Nolan, KA
    Volavka, J
    Mohr, P
    Czobor, P
    [J]. PSYCHIATRIC SERVICES, 1999, 50 (06) : 787 - 792
  • [7] Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder
    Howes, Oliver D.
    Wheeler, Michael J.
    Pilowsky, Lyn S.
    Landau, Sabine
    Murray, Robin M.
    Smith, Shubulade
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (03) : 361 - 367
  • [8] Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia
    Mullins, C. Daniel
    Obeidat, Nour A.
    Cuffel, Brian J.
    Naradzay, John
    Loebel, Antony D.
    [J]. SCHIZOPHRENIA RESEARCH, 2008, 98 (1-3) : 8 - 15
  • [9] Atypical antipsychotic switching versus atypical antipsychotic combination in schizoaffective disorder - A clinical case
    Ballesteros, A.
    Cortes, B.
    Petcu, A.
    Montes, L.
    Jaimes, W.
    Inchausti, F.
    [J]. EUROPEAN PSYCHIATRY, 2016, 33 : S536 - S536
  • [10] Neuromuscular dysfunction in schizophrenia and schizoaffective patients during antipsychotic treatment
    Reznik, I
    Volchek, L
    Reznik, M
    Weizman, A
    Meltzer, HY
    [J]. SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 569 - 569